Due to CTLA-4 upregulation, a second cohort was added to this study in which 31 patients with R/R AML were treated with ipilimumab in combination with azacitidine plus nivolumab in an attempt to further enhance T cell responses [39]. The gene discussed is CTLA4; the disease is acute myeloid leukemia.